<DOC>
	<DOCNO>NCT00124436</DOCNO>
	<brief_summary>Patients treat study protocol BAP089 may respond treatment , subsequently relapse &gt; 75 % baseline disease severity , investigate response treatment alitretinoin . Also , patient respond mild moderate disease investigate additional treatment effect prolongated treatment .</brief_summary>
	<brief_title>Follow-up Efficacy Safety Alitretinoin Severe Chronic Hand Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Hand Dermatoses</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Previous participation protocol BAP089 Response severe , treatment refractory hand dermatitis mild moderate , respond patient relapse 75 % baseline disease Female patient pregnant want become pregnant Female patient child bear potential use commit use two effective method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Patients enrol study protocol BAP089 , whose severe chronic hand dermatitis respond mild moderate disease , relapse</keyword>
</DOC>